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in the incidence and mortality 
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in the era of hyper-ageing, creutzfeldt–Jakob disease (cJD) can become more prevalent as an 
important cause of dementia. this study aimed to evaluate the trends in crude and age-adjusted cJD-
associated mortality and incidence rates in Japan using national vital statistics data on cJD-associated 
deaths among individuals aged over 50 years, as well as the government-funded nationwide CJD 
surveillance data (pertaining to the years 2005–2014) in Japan. The data were analysed using the 





this trend in aging of population, the disease burden of cJD will continue to increase in severity. our 
findings thus recommend that policymakers be aware of the importance of CJD and focus on preparing 
to address the increasing prevalence of dementia.
Characterized by spongiform encephalopathy that causes rapidly-progressing dementia and a rate of high mor-
tality within a year of the onset of clinical symptoms, Creutzfeldt–Jakob disease (CJD) is the most common 
human prion  disease1. CJD is categorized into four different types: variant (vCJD), sporadic (sCJD), familial, 
and  iatrogenic2. While the disease first received the public recognition after the emergence of bovine spongiform 
encephalopathy and the subsequent surge in the global incidence of human vCJD cases between the late 1990s to 
early  2000s3,4, sCJD accounts for approximately 85% of CJD  cases5. Since prion proteins reportedly accumulate in 
brain cells as they  age6,7, sCJD most frequently occurs in late-middle old  age8. Hence, considering the ageing of 
the worldwide population, the potential increase in sCJD cases is a pressing global concern. Indeed, by 2030, the 
global population of individuals aged 60 years or older will increase by 34%9. This rise will shift the demographic 
and epidemiological landscapes of disease.
The global trends of mortality and incidence of CJD are currently trending upwards. For example, the number 
of sCJD cases in Australia rose from 1970 to  201810. In the United States, the Centers for Disease Control and 
Prevention reported an increasing trend in CJD-associated deaths, with an average annual rate of 3.5 per million 
for those over 50 years of  age11,12. Likewise, the age-standardised mortality rate from sCJD in Canada increased 
from 1998 (0.84 per million) to 2013 (1.30 per million)13.
The World Health Organization (WHO) announced the “Decade of Healthy Aging 2020–2030” as a call for 
an increased focus of worldwide attention on population  ageing14. According to the most recent United Nation’s 
World Population Prospects, Japan has the highest proportion of people aged 65 years or older (28% of the 
population)15. Hosted by Japan in 2019, the Group of 20 (G20) also adopted the issue of population ageing as 
one of the main themes of the G20 Health Ministers’ Meeting for the first  time16. In particular, the G20 Health 
Ministers’ called upon the importance of committing to the development and implementation of a national action 
plan to address  dementia17. Because CJD is more prevalent among older individuals who feature an increased 
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vulnerability to progressive dementia, it is imperative to evaluate longitudinal national trends of CJD-associated 
mortality rates and thereby help to inform robust dementia response action and future strategic policy planning.
While previous studies have reported on the epidemiology of regional variations in CJD and its incidence 
and mortality in  Japan18–20, no previous study has investigated the long-term trends in CJD-associated mortality 
and incidence rates in Japan since Doi et al. in  200720. Our study, thus, provides an updated report on the recent 
national trends in CJD-associated mortality and incidence.
Results
the accumulated number of cJD-associated deaths. A total of 2012 CJD-associated deaths were 
recorded between 2005 and 2014. Figure 1 shows the number of CJD-associated deaths stratified into 5-year age 
groups according to sex. The number of CJD-associated deaths rose progressively with age from the age group 
of 50–54 years; the number peaked in the age group of 70–74 years among men (192 deaths over the 10-year 
period) and in the age groups of 70–74 and 75–79 years among women (228 deaths over the 10-year period in 
both age groups).
trends in the crude cJD mortality rates according to sex and age. Figure 2 describes the trends 
in crude mortality rates of CJD-associated deaths in patients over the age of 50 years according to 10-year age 
groups and sex. The detailed numerical values for the age groups are provided in Supplementary Table S1. The 
crude mortality rate per 1,000,000 individuals in the age group of ≥ 80 years increased from 2.4 in 2005 to 7.4 in 
2014 among men and from 2.3 in 2005 to 6.0 in 2014 among women. In the other age groups, the extents of an 
increase in the crude mortality rates were small. In the last year of the study, the crude mortality rates reached 
their highest point in the 10-year study period in the age groups of ≥ 80 years among men and of 70–79 years 
age among women. The results of the joinpoint regression analysis of the crude mortality rates according to the 
10-year age groups are shown in Table 1. Overall and among women, the average annual percentage changes 
(AAPCs) were stable in all the age groups, except for the age group of ≥ 80 years, with a statistically signifi-
cant continuous increase across the entire period. Among men, the AAPCs of the crude mortality rates period 
remained stable in the age groups of 50–59 and 60–69 years across the entire study period, while significant 
increases were observed in the age groups of 70–79 and 80–89 years.
trends in the age-adjusted mortality rates of cJD by sex. The trends in the age-adjusted CJD mor-
tality rates across the entire period are shown in Fig. 3 according to sex along with the results of the joinpoint 
regression analysis. The age-adjusted CJD-associated mortality rates rose significantly over the study period 
among men; the increase was continuous but statistically nonsignificant among women.
Figure 1.  Total number of Creutzfeldt–Jakob Disease-associated death by sex, 2005–2014. The numbers of 
CJD-associated deaths by five-year age groups stratified by sex are shown. The number of CJD-associated deaths 
reached its peak in the 70–74 years age group in male (192 deaths over the 10-year period), and in the 70–74 
and 75–79 years age groups in female (228 deaths over the 10-year period in both age groups).
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cJD incidence by sex. Figure 4 shows the CJD incidence rates for each year stratified by sex. The rates of 
CJD incidence increased continuously among women across the entire study period but reached a peak among 
men in 2013.
trends in the crude cJD incidence rate by age. Figure 5 shows the trends in the crude incidence rate of 
CJD among individuals older than 50 years of age stratified by 10-year age groups and sex. The crude incidence 
rates per 1,000,000 individuals increased continuously in the age groups of 60–69 years or older. The results 
of the joinpoint regression analysis of the crude CJD incidence rates are presented in Table 2 according to the 
10-year age groups. In the age groups of 60–69 and 70–79 years, AAPCs significantly increased across the entire 
study period. In the age group of ≥ 80 years, the rise in the APC between 2005 and 2007 (55.2% increase per year) 
exceeds that between 2007 and 2014 (6.1% increase per year), with a statistically significant, continuous increase 
across the entire period.
trends in the age-adjusted cJD incidence rates. The trends in the overall age-adjusted CJD incidence 
rates across the entire period are shown in Fig. 6 along with the results of the joinpoint regression analysis. The 
Figure 2.  Trends in crude mortality rates (per 1,000,000 population) of Creutzfeldt–Jakob Disease-associated 
death by age and sex, 2005–2014. The trends in crude mortality rates of CJD-associated deaths in patients over 
the age of 50 years by 10-year age groups and sex are described. The detailed numerical values for the age groups 
are available in Supplementary Table S1.
Table 1.  Trend analysis in crude and age-adjusted mortality rate of Creutzfeldt–Jakob disease per 100,000 
by sex and age, 2005–2014. AAR age-adjusted rate, APC annual percentage change, CI confidence interval. 
*Significantly different from zero (p < 0.05).
Age group (years) Average APC (%) [95% CI]
Overall
50–59 4.9 [− 1.8, 12.0]
60–69 0.8 [− 1.8, 3.4]
70–79 2.2 [− 0.2, 4.6]
≥ 80 8.8* [5.7, 11.9]
Male
50–59 2.3 [− 4.8, 9.9]
60–69 2.0 [− 2.4, 6.6]
70–79 3.5* [0.7, 6.3]
≥ 80 13.6* [8.4, 19.0]
Female
50–59 9.0 [− 2.7, 22.1]
60–69  − 0.5 [− 4.6, 3.9]
70–79 1.1 [− 3.1, 5.6]
≥ 80 8.8* [4.9, 12.9]
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Figure 3.  Trends in age-adjusted rates of Creutzfeldt–Jakob Disease-associated death by sex, 2005–2014. The 
trends of age-adjusted CJD mortality rates in the entire period by sex are shown. Average annual percentage 
change (%) [95% confidence interval] in total, male, and female were 3.2* [1.4, 5.1], 3.7* [1.3, 6.0], and 2.9 [− 
0.1, 5.9], respectively. *Significantly different from zero (p < 0.05).
Figure 4.  Numbers of Creutzfeldt–Jakob Disease incidence by sex, 2005–2014. The numbers of CJD incidence 
in each year stratified by sex are shown. The number of CJD incidence continuously increased in females over 
the entire study period, while it reached a peak in 2013 in males.
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overall age-adjusted CJD-associated incidence rates rose significantly over the study period, with an AAPC of 
6.4% (95% CI 4.7–8.1).
Discussion
Our study revealed an increase in the absolute number of deaths, mortality rates, and incidence rates associated 
with CJD—even after age-adjustment—in Japan between 2005 and 2014. The significantly increasing trends in the 
CJD-associated mortality and incidence rates were especially prominent in the older age groups. Previous surveil-
lance data and reviews have described that comparable increasing trends in both mortality and incidence of CJD 
have been observed globally. According to the latest report from the Creutzfeldt–Jakob Disease International 
Surveillance Network, annual mortality rates of sCJD had risen in the most participating countries from 1993 
to  201821. In European countries including the Czech Republic, Slovakia, and the United Kingdom, increases in 
the sCJD incidence have been  reported22–24. According to these studies and the current data, it should be noted 
that Japan might have had higher CJD incidence (more than 4.5 per million in 2014) than other countries. While 
CJD has been considered a rare disease, the phenomenon of population ageing may trigger a rise in the incidence 
of CJD and the attendant socioeconomic and healthcare burdens.
According to the previous CJD-associated mortality analysis conducted from 1979 to 2004 in  Japan20, the 
crude mortality rate reached a peak of 1.3 per million in 2004. Our analysis indicates that the steep trend has 
continued, with 4.1 cases of CJD per million accounted for in 2014 (Supplementary Table S1). While the number 
Figure 5.  Trends in crude incidence rates (per 1,000,000 population) of Creutzfeldt–Jakob Disease, 2005–2014. 
The trends in crude incidence rates of CJD over the age of 50 years by 10-year age groups and sex are shown. 
The crude incidence rates per 1,000,000 population had continuous increases in the 60–69 years age groups or 
older.
Table 2.  Trends in the annual crude and age-adjusted incidence rate of Creutzfeldt–Jakob disease per 
1,000,000 population aged ≥ 50 years by age group, 2005–2014. Within each age group, periods were separated 
as Period 1 and Period 2 when the trend changes were statistically detected in the joinpoint regression analysis 
during the study period. AAR age-adjusted rate, APC annual percentage change, CI confidence interval. 
*Significantly different from zero (p < 0.05).
Age group (years)
Period 1 Period 2
Average APC (%), [95% CI]Years APC (%) Years APC (%)
50–59 2005–2014 5.4 5.4 [− 0.5, 11.6]
60–69 2005–2014 4.0 4.0* [0.2, 8.0]
70–79 2005–2014 6.8 6.8* [4.5, 9.1]
 ≥ 80 2005–2007 55.2 2007–2014 6.1 15.5* [5.3, 26.7]
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of CJD-associated deaths was highest in the 70–79 years age group from 1979 to 2004 in Japan, our crude mortal-
ity analysis showed a predominant upward trend among individuals of over 80 years of age, indicating a shift in 
the CJD disease burden to the more aged population. Concerning the age-adjusted mortality, our results show 
a continuously increasing trend across the study period, with an APC of 3.7% among men and of 2.9% among 
females. These results agree with those found by Doi et al., with an age-adjusted mortality of 3.1% among men 
and 3.9% among women. This increasing trend suggests that CJD will soon aggravate the disease burden in the 
hyper-ageing Japanese society.
The increased CJD-associated mortality rates could be explained by the rise in the rate of CJD incidence. 
The prognosis of CJD is considered poor, with uniform fatality and a median life expectancy of about 6 months 
after diagnosis  worldwide25,26. Hence, as was observed in the present study, the mortality and incidence rates 
are almost identical. Various factors could account for the increase in the rates of CJD incidence: e.g., increased 
awareness of the  disease1, improvement in the accuracy of diagnostic  tests2, and demographic changes charac-
teristic of a hyper-ageing society. While the upward trends in the rates of mortality and incidence may be partly 
attributable to improvements in diagnosis, we propose the ageing of the population as an important contributor 
to the CJD trends in Japan.
According to the Japanese national statistics, the population of individuals of over 65 years of age was 35.58 
million in 2018, accounting for 28.1% of the whole  population27. The Japanese surveillance data indicates that 
approximately 80% of the CJD patients in Japan were sCJD, which is more common among older  individuals28. 
Hence, if the increased CJD-related incidence and mortality are primarily attributable to sCJD, it follows that 
both rates would rise as the population ages. These observations are compatible with our study results, which 
suggest that the number of CJD-associated deaths was highest in the age groups of 70–74 and 75–79 years. From 
a pathophysiological perspective, age may increase the rate of prion protein conversion: the etiological agent of 
prion diseases, including  CJD6,7,29. Also, in our study population, women experienced higher CJD-associated 
deaths and incidence than men, although it has been generally considered that there is no gender predilection 
for  CJD12. A possible explanation for the differences in CJD according to sex may be postmenopausal decreased 
serum oestrogen levels, which could facilitate the maintenance of cellular pathological prion  protein30. Hence, 
the cellular mechanism underlying prion diseases also suggests that the incidence and mortality of sCJD would 
increase in ageing populations.
Considering that dementia has been reported in almost all cases of CJD in  Japan28, the increasing incidence 
of CJD is even more alarming. According to the latest WHO statistics, about 50 million people in the world 
Figure 6.  Trends in age-adjusted rates (per 1,000,000) of Creutzfeldt–Jakob Disease incidence, 2005–2014. The 
trends of the overall age-adjusted CJD incidence rates in the entire period are shown. The overall age-adjusted 
CJD-associated incidence rates showed a significant increase over the period; average annual percentage change 
(%) [95% confidence interval]; 6.4* [4.7, 8.1]. *Significantly different from zero (p < 0.05).
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are estimated to have  dementia31, imposing a substantial worldwide socioeconomic burden; the global social 
costs due to dementia were estimated to be 1.1% of the global gross domestic product in  201532. Approximately 
4.7 million people were living with dementia in Japan in 2015. This figure is projected to rapidly increase to 7 
million people by  202533. Recognising the pressing global concern about dementia, the G20 Health Ministers 
stressed the importance of developing national strategies to improve the quality of care and life of the patients 
with dementia as well those of their  caregivers17. It should further be noted that Japanese patients with CJD were 
reported to have a longer life expectancy (20.9 months on average) following diagnosis than those from other 
countries (approximately 6 months as noted above)28, which would pose additional socioeconomic impacts on 
the patients’ caregivers if the mortality and incidence rates continue to rise at the current  rates34. While CJD 
still remains a rare disease, the trends identified by the present study warrant attention by public health authori-
ties and indicate the need for effective policy measures to mitigate the disease burden of CJD, from caregiver’s 
perspectives in particular.
While this study benefits from being the first to use national vital statistics and surveillance data to perform a 
joinpoint regression analysis of trends in CJD-associated incidence and mortality in Japan, it is subject to several 
limitations. First, as we analysed the causes of death based on the information provided by death certificates, we 
may have underestimated the CJD-associated death rates. Second, the rate of CJD incidences could have been 
further underestimated due to the voluntary nature of the CJD surveillance. Third, we used a specific ICD-10 
code (A81.0 “Creutzfeldt–Jakob disease”) from the vital statistics to obtain our data, which made it impossible to 
determine the accuracy of the recorded causes of death. Specifically, the patients with CJD may have a number of 
complications, such as infections, heart failure, and respiratory failure, common in the older populations. Hence, 
the attribution of the cause of death to CJD may have been recorded inappropriately in some cases. Despite the 
limitations, our present study underscores the significantly increasing trends in CJD-associated mortality and 
incidence across a 10-year period in the era of ageing.
In conclusion, we revealed the increasing trends of CJD-associated incidence and mortality using joinpoint 
regression analysis. The extent of increase was greater among individuals older than 70 years of age; hence, the 
increased rated of CJD-associated incidence and mortality may not only be attributable to increased disease 
awareness but also be attributable to the increasingly ageing population. The severe socioeconomic burdens on 
caregivers imposed by CJD-induced dementia also warrant the attention of policymakers and stress the need for a 
mitigative action plan with particular focus on preparations to handle an increase in the prevalence of dementia.
Methods
Data source. The data were acquired from two different sources. First, we examined the Japanese Vital 
Statistics data from 2005 to 2014 to obtain data on CJD-associated  mortality35. In Japan, death certificates are 
issued by physicians and gathered by the Ministry of Health, Labour and Welfare Japan (MHLW). The data on 
patients’ basic demographics are anonymized and subsequently coded to convey the underlying causes of death 
in accordance with the designations used in the International Classification of Diseases, 10th revision (ICD-10). 
CJD-associated mortality was defined using the ICD-10 codesA81 (A81.0), named “Creutzfeldt–Jakob disease,” 
according to the method used by previous  studies12,20. Thus, in the present study, data on CJD-associated mor-
tality were of the same type as those used in previous studies. Population data were obtained from the 2005 and 
2010 censuses. Since the population census is only performed every 5 years in Japan, the government provides 
projected data for the intervals between census years (2006–2009, 2011–2014). All the data used in the present 
study, therefore, corresponded to official Japanese statistics, as managed by the Statistics Bureau, Ministry of 
Internal Affairs and  Communications36.
Second, we obtained the CJD incidence rates from 2005 to 2014 from the registry data of CJD administered by 
the Surveillance Committee, which is funded by the  MHLW28. Although the data is considered reliable because 
the Surveillance Committee convenes biannually to thoroughly confirm whether the reported cases meet the 
WHO’s diagnostic criteria for CJD, due to the voluntary nature of the case reports to the Committee, a few years 
may elapse before the incidence data correspond to the actual numbers.
Data of patients aged over 50 years were stratified by age and sex to calculate crude and age-adjusted mortal-
ity rates per 1,000,000 individuals. Due to the lack of sex-stratified incidence data, the age-adjusted incidence 
rates were calculated en bloc. The age groups were categorised as follows: 50–59 years, 60–69 years, 70–79 years, 
and ≥ 80 years. All patients aged less than 50 years were excluded from the analysis due to the negligible number 
of CJD-associated deaths in the age group.
Statistical analyses and data processing. A joinpoint regression model was implemented with the 
Joinpoint Regression Program (version 4.8.0.1, April 2020, Statistical Research and Applications Branch, 
National Cancer Institute, USA). The APCs between trend-change points were determined with 95% confidence 
intervals (CI). To calculate the age-adjusted rates of CJD-associated mortality and incidence, we used the direct 
age-standardisation method with the 2005 Japanese population split into 10-year age groups as the standard 
population. To compare the differences in mortality and incidence trends between population subgroups, the 
average annual percentage change AAPC was computed for the entire period. The threshold for statistical sig-
nificance was defined as p value < 0.05, which indicated the level at which the slope differed from zero.
ethical approval. We used the publicly available data published by the Ministry of Health, Labour and 
Welfare and the Statistics Bureau of the Ministry of Internal Affairs and Communications Japan. The study was 
approved by the institutional review board of Okayama University Hospital with a waiver for informed consent 
because the study intended to retrospectively analyse open data (No. 1910-009). All research methods were per-
formed in accordance with relevant guidelines and regulations.
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